Pharmaceutical research and development company Serina Therapeutics has partnered with the Scripps Research Institute to jointly develop polymer-antibody drug conjugates (Polymer-ADCs).
Terms and financial details of the deal have not been revealed.
Serina Therapeutics president and chief executive officer Dr Randall Moreadith said antibody drug conjugates represent an exciting area of drug development in oncology.
"The ability to target antibodies that are "pay-loaded" with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates," Moreadith added.
"Our polymer technology platform is uniquely suited to advance this field."
Serina is advancing novel therapeutics for Parkinson's disease, cancer, inflammation, pain and metabolic disorders using its proprietary polymer technology.
It has now advanced two lead clinical candidates through preliminary proof-of-concept in animal models and is moving these compounds into IND-enabling studies in 2012-2013.
